Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 135, Issue 3, Pages 468-475Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPZ5JY6FCVNMOT
Keywords
Atypical squamous cells of undetermined significance; ASC-US; Cervical cancer screening; Cervical intraepithelial neoplasia; Cytology; Genotype; Human papillomavirus; HPV DNA testing; Triage
Categories
Funding
- Roche Molecular Systems, Pleasanton, CA
Ask authors/readers for more resources
This study evaluated the clinical performance of the cobas 4800 HPV Test (Roche Molecular Systems, Pleasanton, CA) for high-risk human papillomavirus (HR-HPV) testing with individual HPV-16/HPV-18 genotyping in women 21 years or older with atypical squamous cells of undetermined significance (ASC-US). Women (N = 47,208) were recruited in the United States during routine screening, and liquid-based cytology and HPV testing were performed. The ASC-US prevalence was 4.1% (1,923/47,208), and 1,578 women underwent colposcopy with valid results. The cobas 4800 HPV Test demonstrated performance comparable to the Hybrid Capture 2 test (QIAGEN, Gaithersburg, MD) for the detection of cervical intraepithelial neoplasia (CIN) grade 2 or worse and grade 3 or worse. HPV-16/HPV-18+ women had a greater absolute risk of CIN 2 or worse compared with pooled HR-HPV+ and HR-HPV women (24.4%, 14.0%, and 0.8%, respectively). The cobas 4800 HPV Test is clinically validated for ASC-US triage. HPV-16/HPV-18 genotyping can identify women at highest risk for high-grade cervical disease, and this additional risk stratification may be used in formulating patient management decisions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available